登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C10H14N2O4 · H2O
化学文摘社编号:
分子量:
244.24
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
产品名称
(S)-3-(3,4-二羟基苯基)-2-肼基-2-甲基丙酸 一水合物, United States Pharmacopeia (USP) Reference Standard
InChI
1S/C10H14N2O4.H2O/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6;/h2-4,12-14H,5,11H2,1H3,(H,15,16);1H2/t10-;/m0./s1
SMILES string
O.C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O
InChI key
QTAOMKOIBXZKND-PPHPATTJSA-N
grade
pharmaceutical primary standard
API family
carbidopa
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
human ... DDC(1644)
正在寻找类似产品? 访问 产品对比指南
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Application
Carbidopa USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Carbidopa and Levodopa Extended-Release Tablets
- Carbidopa and Levodopa Orally Disintegrating Tablets
- Carbidopa and Levodopa Tablets
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2
存储类别
11 - Combustible Solids
wgk
WGK 3
Q. Alan Xu, Timothy L. Madden
Analytical Methods for Therapeutic Drug Monitoring and Toxicology, 80-80 (2011)
Mohseni Mehran S M et al.
Journal of clinical and diagnostic research : JCDR, 7(6), 1004-1007 (2013-08-02)
According to many studies, sprouted fava beans are a rich source of levo-dihydroxy phenylalanine (L-dopa) the precursor of dopamine, and they are now being investigated for use in the management of Parkinson's disease. The addition of Carbidopa (C-dopa) can reduce
J T Hutton et al.
Neurology, 42(1 Suppl 1), 51-56 (1992-01-01)
Parkinson's disease patients treated chronically with levodopa often develop fluctuations in motor response. Motor fluctuations can be attributed in part to oscillating plasma levodopa concentrations. A controlled-release formulation containing 200 mg of levodopa and 50 mg of carbidopa provides superior
A Castro et al.
Neurologia (Barcelona, Spain), 20(4), 180-188 (2005-05-14)
Levodopa remains the mainstay treatment for Parkinson's disease (PD). Chronic treatment is associated with motor complications (MC) that marred the clinical benefit of levodopa. These problems and experimental data in cell cultures indicating a neurotoxic effect of levodopa have led
Robert A Hauser
Expert review of neurotherapeutics, 12(2), 133-140 (2012-02-01)
Levodopa (LD) remains the most effective medication to treat Parkinson's disease (PD). However, most patients develop motor fluctuations and dyskinesias with long-term LD use. It is thought that these response complications are due, at least in part, to LD's short
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持